DP Medical Ltd has secured a deal with Sheffield Teaching Hospitals NHS Foundation Trust (STHFT) to become the first NHS Trust in the country to adopt ZedScan™ as part of its cervical cancer care pathway.
The ground-breaking system, which includes its patented Electrical Impedance Spectroscopy technology, offers quicker and more accurate detection of cervical neoplasia delivering results in real-time, enabling clinicians to improve patient management.
ZedScan enables clinicians to make more informed decisions at a patient’s first visit, thus benefiting both the patient and hospital. The system allows for a more efficient pathway and reduced morbidity for the patient.
The Trust has signed a three-year contract with DP Medical to supply the system which comprises of a handheld device, software and disposable sensors. This follows the evaluation of over 400 patients at STHFT where the ZedScan system was routinely used within a clinical setting.
ZedScan, developed by Zilico Ltd, will also provide significant long-term health-economic benefits to STHFT.
Rob Atkinson, UK Business Development Manager and ZedScan product specialist for DP Medical said: “This is a really momentous step for the way patients are managed within the cervical cancer care pathway and we’re delighted that STHFT is the first trust to have fully adopted ZedScan.
“Ensuring NHS clinicians have access to the best technology to improve diagnosis in this area of healthcare is vital – and ZedScan certainly meets that criteria.
“We are now looking forward to sharing the results of the case study from STHFT to encourage other Trusts around the country to consider adopting ZedScan.”
Dr David Throssell, Medical Director of Sheffield Teaching Hospitals, said: “We pride ourselves on being at the forefront of healthcare innovation and this news reinforces our status as pioneers in new medical technology – particularly as this was a system developed together at the University of Sheffield and the Trust.”